813 results
Page 5 of 41
6-K
EX-99.2
8jqaaz
2 Sep 22
Current report (foreign)
9:44am
6-K
EX-99.1
vpu4c6j
2 Sep 22
Current report (foreign)
9:44am
6-K
EX-99.1
a83f910
17 Aug 22
Sanofi provides update on amcenestrant clinical
1:18pm
6-K
EX-99.1
hvua3w n1r
11 Aug 22
Current report (foreign)
3:24pm
6-K
EX-99.2
l5jfbtpfaax66b5d tw
8 Aug 22
Sanofi and Innovent Biologics enter strategic
4:27pm
6-K
EX-99.1
52vwr8eiuaqr xsf9z
8 Aug 22
Sanofi and Innovent Biologics enter strategic
4:27pm
6-K
EX-99.1
mhq1kbvtono2ni d5vsj
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.1
4leywdm
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.2
z7c68g ird
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
9ka0cr884cq f6yzpj
20 Jul 22
Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
12:38pm
6-K
EX-99.1
my9pac5
13 Jul 22
Current report (foreign)
1:40pm
6-K
EX-99.2
f47a1njuh9n9k8t
13 Jul 22
Current report (foreign)
1:40pm
6-K
EX-99.1
q60nyj h3
8 Jul 22
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
11:01am
6-K
EX-99.1
ovy3dyakn
30 Jun 22
Current report (foreign)
12:10pm
6-K
EX-99.3
x6puh9wp7uizuo
28 Jun 22
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
3:59pm
6-K
EX-99.1
q3b1t548lv8ow1a2
28 Jun 22
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
3:59pm
6-K
EX-99.2
zp8mifna9dnlvdc88
28 Jun 22
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
3:59pm
6-K
EX-99.1
hzvhnu3k
16 Jun 22
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
1:20pm
6-K
EX-99.2
aj7nmmzgmobdso
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.3
3mwjgm5 y79p7xm
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm